Characterization of LY2775240, a selective phosphodiesterase‐4 inhibitor, in nonclinical models and in healthy subjects

ABSTRACT: LY2775240 is a highly selective, potent and orally‐administered inhibitor of phosphodiesterase 4 (PDE4), and is being investigated as a treatment option for inflammatory disorders, such as psoriasis. LY2775240 was investigated in rodent and rhesus monkey nonclinical models. Treatment with...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Dipak R., Urva, Shweta, Ho, Stephen, Buckman, Cody J., Ma, Yanfei, Lim, Jean, Sissons, Sean E., Zuniga, Mary S., Philips, Diane, Cox, Karen, Dairaghi, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212710/
https://www.ncbi.nlm.nih.gov/pubmed/33382916
http://dx.doi.org/10.1111/cts.12968

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212710/
https://www.ncbi.nlm.nih.gov/pubmed/33382916
http://dx.doi.org/10.1111/cts.12968

Ejemplares similares